Response and resistance with BRAF inhibitors: Mechanisms, markers and unanswered questions

Bookmark and Share
Sorry, this item is currently unavailable.
Published: 19 Mar 2015
Views: 2610
Dr Keith Flaherty - Massachusetts General Hospital Cancer Centre, Boston, USA

Dr Flaherty BRAF inhibitors as a strategy for the treatment of metastatic melanoma at the Society for Melanoma Research (SMR) International Congress 2014 in Switzerland.

See also:

BRAF 'behind the scenes' in melanoma: A scientific story of discovery

Connecting science, practice and patient outcomes: Use of BRAF inhibitors for treating metastatic melanoma in clinical practice

GSK has paid for the organisation costs of the symposium and honoraria for the chairperson and speakers. GSK has contributed to the agenda and content of the meeting.

Zinc code: OF/ONC/0003/15d

Date of preparation: February 2015